Depression has been tied to a two-fold increased risk offor epilepsy and a suboptimal response to initial therapy, ...
AI helped identify patients with drug-resistant epilepsy who might benefit from surgery, and it highlighted missing tests and ...
Individuals with epilepsy and depression had a higher psychiatric comorbidity burden linked to shorter duration of initial ...
The AAN’s first-ever functional seizure guideline targets stigma and unnecessary treatment, offering clearer diagnostic steps ...
Aeovian Pharmaceuticals Raises $55 Million to Advance First-in-Class Selective mTORC1 Inhibitor for Tuberous Sclerosis ...
A combination of missed prevention opportunities and health inequalities can result in the early deaths of people living with ...
The Neurology Advisor Team spoke with Shilpa Reddy, MD, MMHC at AES 2025 in Atlanta, Georgia. Neurology Advisor: “Can you describe your work in neuromodulation?” ...
Wigan Today on MSN
A Wigan mum has spoken out about her five-year-old son's medical treatment after he was diagnosed with lung damage
A mum is looking into taking legal action against Wigan Infirmary over the care given to her young son. Leah Anders, from ...
MedPage Today on MSN
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...
Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...
TipRanks on MSN
Lipocine advances phase 3 trial for PPD treatment
Lipocine ( ($LPCN) ) has shared an announcement. On December 16, 2025, Lipocine announced that its Phase 3 clinical trial for LPCN 1154, an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback